Adjuvant chemotherapy following chemoradiation treatment in patients with locally advanced stage III or IV nasopharyngeal carcinoma where CISplatin is contraindicated or not tolerated.
CARBOplatin AUC4 and 5-Fluorouracil 600mg/m2 with Radiotherapy
Chemoradiation treatment for locally advanced (stage III to IV) squamous cell carcinoma (SCC) of the head and neck, where treatment with CISplatin is not appropriate (AUC 5).
Chemoradiation treatment of stage III and IV locally advanced nasopharyngeal carcinoma in patients where CISplatin is contraindicated or not tolerated.
CARBOplatin AUC (1.5) Chemoradiation Therapy-7 days
Chemoradiation commencing 3 to 8 weeksafter the completion of induction chemotherapy with TPF in patients with Stage III or IV locally advanced squamous cell carcinoma (SCC) of the head and neck.
Cetuximab (weekly), Carboplatin AUC 5 and 5-Fluorouracil 1000mg/m2/day Therapy-21 day cycle
Chemoradiation treatment for locally advanced nasopharnygeal carcinoma.
00385d
Chemoradiation treatment for locally advanced unresectable head and neck squamous carcinoma (SCC) in patients who cannot tolerate three weekly CISplatin regimens.
Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.
Recurrent, advanced or metastatic head and neck squamous cell carcinoma (SCC) in patients with comorbidities or as palliative treatment in patients unsuitable for combination chemotherapy
As monotherapyfor the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.
As monotherapyfor the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.
Pembrolizumab, CARBOplatin (AUC 5) and 5- Fluorouracil Therapy
Pembrolizumab is indicated, in combination with CARBOplatin and 5- fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.
Pembrolizumab, CISplatin and 5- Fluorouracil Therapy
Pembrolizumab is indicated, in combination with CISplatin and 5-fluorouracil, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.
Treatment of patients with progressive, locally advanced or metastatic differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
